Quantcast

Latest Amgen Stories

2014-09-22 08:29:14

FDA Submission Reinforces Commitment to Addressing Significant Unmet Needs for Patients With Acute Lymphoblastic Leukemia, an Aggressive Cancer With Limited Treatment Options THOUSAND

2014-09-15 16:29:02

Data Presented at the American Society of Bone and Mineral Research 2014 Annual Meeting THOUSAND OAKS, Calif., Sept.

2014-09-15 16:28:40

Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016 THOUSAND OAKS, Calif. and BRUSSELS, Sept.

2014-09-14 20:20:15

Analysis From SHIFT Study Shows Ivabradine Reduced Cardiovascular Death or Hospitalization for Worsening Heart Failure Independent of Baseline Blood Pressure With Similar Safety Profile Across Groups THOUSAND

2014-09-10 08:32:41

Data Include Eight Year Analyses of Bone Mineral Density Results for Prolia® (Denosumab) and Further Evidence for Significant Bone-Building With Romosozumab THOUSAND OAKS, Calif., Sept.

2014-09-05 16:23:16

THOUSAND OAKS, Calif., Sept. 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept.

2014-09-02 08:30:29

First Marketing Authorization Application for an Oncolytic Immunotherapy in the European Union THOUSAND OAKS, Calif., Sept.

2014-09-02 08:29:42

Represents First Marketing Authorization Application in the European Union for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Sept.

2014-08-28 08:28:27

Represents First BLA Submission for a PCSK9 Inhibitor THOUSAND OAKS, Calif., Aug.


Word of the Day
dwale
  • The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
  • A sleeping-potion; a soporific.
  • To mutter deliriously.
The word 'dwale' comes from an Old English word meaning 'error, doubt, delusion.'
Related